WO2014194242A3 - Flt3 inhibitors and uses thereof - Google Patents

Flt3 inhibitors and uses thereof Download PDF

Info

Publication number
WO2014194242A3
WO2014194242A3 PCT/US2014/040317 US2014040317W WO2014194242A3 WO 2014194242 A3 WO2014194242 A3 WO 2014194242A3 US 2014040317 W US2014040317 W US 2014040317W WO 2014194242 A3 WO2014194242 A3 WO 2014194242A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
compounds
flt3
kinases
diseases
Prior art date
Application number
PCT/US2014/040317
Other languages
French (fr)
Other versions
WO2014194242A2 (en
Inventor
Divya Chaudhary
Rosana Kapeller-Libermann
Original Assignee
Nimbus Iris, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Iris, Inc. filed Critical Nimbus Iris, Inc.
Publication of WO2014194242A2 publication Critical patent/WO2014194242A2/en
Publication of WO2014194242A3 publication Critical patent/WO2014194242A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods of using compounds of formula I: or compositions thereof for the inhibition of FLT3, and the treatment of FLT3-mediated disorders'. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with regulation of signaling pathways implicating FL T3 kinases. Such diseases, disorders, or conditions include those described herein. Compounds provided by this invention are also useful for the study of FL T3 enzymes in biological and pathological phenomena; the study of intracellular signal transduction pathways occurring in bodily tissues; and the comparative evaluation of new FL T3 inhibitors or other regulators of kinases, signaling pathways, and cytokine levels in vitro or in vivo.
PCT/US2014/040317 2013-05-31 2014-05-30 Flt3 inhibitors and uses thereof WO2014194242A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829829P 2013-05-31 2013-05-31
US61/829,829 2013-05-31

Publications (2)

Publication Number Publication Date
WO2014194242A2 WO2014194242A2 (en) 2014-12-04
WO2014194242A3 true WO2014194242A3 (en) 2015-10-29

Family

ID=51989542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/040317 WO2014194242A2 (en) 2013-05-31 2014-05-30 Flt3 inhibitors and uses thereof

Country Status (1)

Country Link
WO (1) WO2014194242A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015014034A2 (en) * 2013-01-10 2017-07-11 Nimbus Iris Inc irak inhibitors and uses thereof
CN112500338A (en) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 Compounds and their use for modulating hemoglobin
CA2925211A1 (en) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
CN113874015B (en) 2018-12-21 2024-05-24 细胞基因公司 Thienopyridine inhibitors of RIPK2
CN112773797A (en) * 2019-11-11 2021-05-11 江苏恒瑞医药股份有限公司 Application of pyrrolo six-membered heterocyclic compound in preparation of medicine for treating FLT3 mutant tumor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323214B1 (en) * 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US20110282056A1 (en) * 2008-01-22 2011-11-17 Merck Patent Gmbh Protein kinase inhibitors and use thereof
US20120283238A1 (en) * 2011-01-10 2012-11-08 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US20130231328A1 (en) * 2012-01-10 2013-09-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323214B1 (en) * 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US20110282056A1 (en) * 2008-01-22 2011-11-17 Merck Patent Gmbh Protein kinase inhibitors and use thereof
US20120283238A1 (en) * 2011-01-10 2012-11-08 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US20130231328A1 (en) * 2012-01-10 2013-09-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADEPU ET AL.: "Novel thieno[2,3-d]pyrimidines: their design, synthesis, crystal structure analysis and pharmacological evaluation.", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 10, no. 29, 2012, pages 5554 - 5569, XP055232212, ISSN: 1477-0520, Retrieved from the Internet <URL:http://www.researchgate.net/publicabon/227342543_Novel_thieno23-dpyrimidines_their_design_synthesis_crystal_structure_analysis_and_pharmacological_evaluation> *

Also Published As

Publication number Publication date
WO2014194242A2 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
WO2014194245A3 (en) Cdk8 inhibitors and uses thereof
MA32272B1 (en) Inhibitors of pyrazole [3,4-b] pyridine raf
WO2014194242A3 (en) Flt3 inhibitors and uses thereof
WO2012048129A3 (en) Inhibitors of polo-like kinase
MA38380A1 (en) Quinazoline inhibitors of activation of mutant forms of epidermal growth receptor (EGFR)
CA2871471C (en) Dna-pk inhibitors
NZ720511A (en) Compounds useful as inhibitors of atr kinase and combination therapies thereof
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
WO2010030813A3 (en) Methods for inhibiting ocular angiogenesis
EA201290894A1 (en) AZETIDINE DERIVATIVES OF PIPERIDIN-4-ILA AS JAK1 INHIBITORS
TN2016000458A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer.
MX2014014828A (en) 5-azaindazole compounds and methods of use.
WO2014143242A8 (en) Compounds useful as inhibitors of atr kinase
WO2009155527A3 (en) Phosphatidylinositol 3 kinase inhibitors
WO2011058474A8 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
EA201270480A1 (en) NEW CONNECTIONS
MX2012007273A (en) Pteridinones as inhibitors of polo - like kinase.
EA201590624A1 (en) CYCLIC ETHERS OF PYRAZOL-4-IL-HETEROCYCLIL-CARBOXAMIDE COMPOUNDS AND METHODS OF THEIR APPLICATION
MX2016008624A (en) Serine/threonine kinase inhibitors.
MX347917B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof.
EP3363797A8 (en) Oral dosage form of apoptosis signal-regulating kinase inhibitors
UA112285C2 (en) Compounds and compositions as protein kinase inhibitors
PT2150530E (en) Substituted sulfonamide derivatives
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
PH12013502369A1 (en) Diazacarbazoles and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14803495

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14803495

Country of ref document: EP

Kind code of ref document: A2